Insightec

WikiDoc Resources for Insightec
Articles
Most recent articles on Insightec Most cited articles on Insightec Review articles on Insightec Articles on Insightec in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Insightec Images of Insightec Photos of Insightec Podcasts & MP3s on Insightec Videos on Insightec
Evidence Based Medicine
Cochrane Collaboration on Insightec Bandolier on Insightec TRIP on Insightec
Clinical Trials
Ongoing Trials on Insightec at Clinical Trials.gov Trial results on Insightec Clinical Trials on Insightec at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Insightec NICE Guidance on Insightec NHS PRODIGY Guidance FDA on Insightec CDC on Insightec
Books
Books on Insightec
News
Insightec in the news Be alerted to news on Insightec News trends on Insightec
Commentary
Blogs on Insightec
Definitions
Definitions of Insightec
Patient Resources / Community
Patient resources on Insightec Discussion groups on Insightec Patient Handouts on Insightec Directions to Hospitals Treating Insightec Risk calculators and risk factors for Insightec
Healthcare Provider Resources
Symptoms of Insightec Causes & Risk Factors for Insightec Diagnostic studies for Insightec Treatment of Insightec
Continuing Medical Education (CME)
CME Programs on Insightec
International
Insightec en Espanol Insightec en Francais
Business
Insightec in the Marketplace Patents on Insightec
Experimental / Informatics
List of terms related to Insightec

InSightec Ltd., founded in 1999, is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, private investors and employees. InSightec was founded specifically to develop MR (magnetic resonance) guided Focused Ultrasound technology. Headquartered in Tirat Hacarmel near Haifa, Israel, with US headquarters in Dallas Texas, the company has over 100 employees.

InSightec developed ExAblate® 2000 – a surgical system that combines Magnetic resonance imaging and Focused Ultrasound to non-invasively treat tumors inside the body without the need for incisions. During this outpatient procedure, the patient lies inside an MRI scanner, which provides three-dimensional images of the diseased tissue and surrounding area, enabling precise guidance of the ultrasound waves. High intensity focused ultrasound waves are then directed into the body at specific tissue, raising the temperature of the targeted tissue to 65 to 85 degrees Celsius, destroying it. The imaging capabilities of the MRI scanner provide real-time feedback on all aspects of the procedure which gives the physician a high degree of control over its therapeutic outcome.

ExAblate® 2000 has been approved to treat uterine fibroids, and is currently in use in the US, Israel, Europe and Asia. Clinical trials are being conducted to evaluate ExAblate® 2000 for treatment of other diseases such as breast, liver, bone and brain cancers.

See also

• Magnetic Resonance guided Focused Ultrasound
• Magnetic resonance imaging
• Medical ultrasonography
• Uterine fibroid

External links

• ExAblate® 2000
• MMS InSightec Investors
• InSightec Company Website
• Mayo Clinic

Template:WikiDoc Sources